VANCOUVER, British Columbia, Feb. 10, 2021 -- InvestorsHub NewsWire -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the "Company" or...
VANCOUVER, British Columbia, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage...
Algernon Receives U.S. FDA Clearance for Multinational Phase 2b/3 Human Study to Evaluate Ifenprodil as a Potential Therapeutic for COVID-19 VANCOUVER, British Columbia, June 04, 2020...
Algernon Receives Positive Feedback from U.S. FDA for Ifenprodil COVID-19 Human Trial; Appoints U.S. Ambassador (Rtd) Howard Gutman to Advisory Board VANCOUVER, British Columbia, Canada...
Algernon Announces Filing of U.S. FDA Pre-IND Meeting Request for Ifenprodil Coronavirus Trial, Expanded Access, and Emergency Use VANCOUVER, British Columbia, Canada -- March 13, 2020...
Algernon Explores the Use of NP-120 (Ifenprodil) as a Novel Treatment for Coronavirus VANCOUVER, British Columbia, Canada -- March 6, 2020 -- InvestorsHub NewsWire -- Algernon...
Algernon Pharmaceuticals Announces Russian Athletic Performance Enhancing Drugs Bemethyl (NP-135) and Bromantane (NP-160) Exhibited Potent Anti-Fibrotic Activity in NASH and CKD...
Algernon Pharmaceuticals Announces Ifenprodil (NP-120) an NDMA Receptor Antagonist as its Lead Drug That Reduced Fibrosis in a Recent Idiopathic Pulmonary Fibrosis Study by...
Algernon Pharmaceuticals’ NP-120 Reduced Fibrosis in an Idiopathic Pulmonary Fibrosis Study by 56% Outperforming USFDA Approved Treatments...
#outlook a {padding:0;} body {width:100%; -webkit-text-size-adjust:100%; -ms-text-size-adjust:100%; margin:0; padding:0;} .ReadMsgBody {width:100%;} .ExternalClass...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.005 | 6.66666666667 | 0.075 | 0.085 | 0.075 | 25917 | 0.08 | CS |
4 | 0.01 | 14.2857142857 | 0.07 | 0.09 | 0.065 | 30357 | 0.07840457 | CS |
12 | -0.005 | -5.88235294118 | 0.085 | 0.1 | 0.06 | 32889 | 0.07573332 | CS |
26 | -0.0475 | -37.2549019608 | 0.1275 | 0.1325 | 0.06 | 26257 | 0.08616871 | CS |
52 | 0 | 0 | 0.08 | 0.165 | 0.06 | 27338 | 0.10042845 | CS |
156 | -2.0075 | -96.1676646707 | 2.0875 | 2.25 | 0.05 | 18221 | 0.21022733 | CS |
260 | 0.06 | 300 | 0.02 | 2.975 | 0.01125 | 327165 | 0.07809234 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約